Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1)

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 1-2, 2010, Pages 206-214

  Rui, Wang ^a   Bing, Feng ^a   Hai Zhu, Song ^a   Wei, De ^b   Long Bang, Chen ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemoresistance; Docetaxel; MicroRNA profile; Non small cell lung carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; MICRORNA; TAXOID;

ARTICLE; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MICROARRAY ANALYSIS; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; MICROARRAY ANALYSIS; MICRORNAS; TAXOIDS;

EID: 77951945516     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00964.x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin. 2008, 58:71-96.
2. Jalal SI, Ademuyiwa FO, Hanna NH. The role of maintenance chemotherapy in advanced non small cell lung cancer. Curr Opin Oncol. 2009, 21:110-5.
3. Edelman MJ, Gandara DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol. 1996, 37:385-93.
4. Ding S, Chamberlain M, McLaren A. Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer. 2001, 85:1175-84.
5. Alli E, Bash-Babula J, Yang JM. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res. 2002, 62:6864-9.
6. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell. 2003, 3:51-62.
7. Meng H, Tanigawa N, Hao CY. Chemoresponse to docetaxel correlates with expression of the survivin splicing variants in patients with gastric cancer. Hepatogastroenterology. 2007, 54:1934-40.
8. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009, 35:255-6.
9. Kamath K, Wilson L, Cabral F. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem. 2005, 280:12902-7.
10. Chekanova JA, Belostotsky DA. MicroRNAs and messenger RNA turnover. Methods Mol Biol. 2006, 342:73-85.
11. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2007, 96:R40-4.
12. Maatouk D, Harfe B. MicroRNAs in development. Sci World J. 2006, 6:1828-40.
13. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med. 2009, 60:167-79.
14. Ma L, Weinberg RA. MicroRNAs in malignant progression. Cell Cycle. 2008, 7:570-2.
15. Walker S. Updates in non-small cell lung cancer. Clin J Oncol Nurs. 2008, 12:587-96.
16. Gkiozos I, Charpidou A, Syrigos K. Developments in the treatment of non-small cell lung cancer. Anticancer Res. 2007, 27:2823-7.
17. Bernstein ED, Herbert SM, Hanna NH. Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer. Ann Surg Oncol. 2006, 13:291-301.
18. Besse B, Le Chevalier T. Adjuvant or induction cisplatin-based chemotherapy for operable lung cancer. Oncology. 2009, 23:520-7.
19. Chiappori A, Simon G, Williams C. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology. 2005, 68:382-90.
20. Belani CP. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol. 2002, 29:4-9. TAX 326 Study Group
21. Rubio-TerrÈs C, Tisaire JL, Kobina S. Cost-minimisation analysis of three regimens of chemotherapy (docetaxel-cisplatin, paclitaxel-cisplatin, paclitaxel-carboplatin) for advanced non-small-cell lung cancer. Lung Cancer. 2002, 35:81-9.
22. Carrión RP, Gracián AC, Hernandez PS. Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2007, 8:425-8.
23. Longo-Sorbello GS, Chen B, Budak-Alpdogan T. Role of pemetrexed in non-small cell lung cancer. Cancer Invest. 2007, 25:59-66.
24. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994, 5:S3-6.
25. Geney R, Ungureanu M, Li D. Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med. 2002, 40:918-25.
26. McGrogan BT, Gilmartin B, Carney DN. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008, 1785:96-132.
27. SUN Hai, GENG Jian, JIN Jie. Establishment and characterization of a docetaxel-resistant variant of human lung adenocarcinoma cell line SPC-A1. China Oncol. 2007, 17:283-7.
28. Tong AW. Small RNAs and non-small cell lung cancer. Curr Mol Med. 2006, 6:339-49.
29. Raponi M, Dossey L, Jatkoe T. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009, 69:5776-83.